Merck & Co. stock pre-market at EUR 131.82: plus 0.08 percent
Published on 09/30/2026 at 08:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co. stock is at EUR 131.82 pre-market at Lang & Schwarz at 8:28 a.m. CEST on September 30, 2026. The price is up 0.08 percent versus the EUR 131.71 Lang & Schwarz prior close from September 29, 2026.
Pre-market trading
The Lang & Schwarz bid was EUR 131.66 and the ask was EUR 131.98. The quote is a euro indication ahead of the Xetra open.
U.S. cancer application withdrawn
Yahoo Finance reported that Merck & Co., Inc. and Daiichi Sankyo announced on September 25, 2026, that they voluntarily withdrew the U.S. application for ifinatamab deruxtecan in adults with extensive-stage small-cell lung cancer whose disease progressed during or after platinum-based chemotherapy.
The report said the partners made the withdrawal following discussions with the U.S. Food and Drug Administration, which concluded that the submitted evidence, including Phase 2 results, did not satisfy accelerated-approval requirements. The report also said Merck and Daiichi Sankyo continue development through the Phase 3 IDeate-Lung02 trial.
